摘要
目的:探讨恩替卡韦辅助治疗对乙肝肝硬化失代偿期并大量腹水患者的影响。方法:收治乙肝肝硬化失代偿期并大量腹水患者60例,随机分为对照组和观察组,各30例。对照组给予对症支持治疗,观察组在对照组基础上联合恩替卡韦治疗。结果:观察组治疗总有效率明显高于对照组(P<0.05);两组患者治疗后尿量明显增加(P<0.05);两组腹围、体重明显减少(P<0.05),且观察组治疗后增加和减少较对照组治疗后更为明显(P<0.05)。结论:恩替卡韦辅助治疗乙肝肝硬化失代偿期并大量腹水患者疗效显著,可明显减少腹水。
Objective：To investigate the effect of entecavir adjuvant therapy on patients with decompensated cirrhosis and massive ascites.Methods：60 patients with hepatitis B cirrhosis decompensated and a large number of ascites were selected,they were randomly divided into the control group and the observation group with 30 cases in each.The control group was treated with symptomatic support,and the observation group was treated with entecavir on the basis of the control group.Results：The total effective rate of the treatment in the observation group was significantly higher than that in the control group（P〈0.05）;the urine volume in the two groups increased significantly（P〈0.05）,while the abdominal circumference and weight decreased significantly（P〈0.05）,and the increase and decrease after treatment in the observation group were more obviously than those in the control group（P〈0.05）.Conclusion：Entecavir is effective in the treatment of hepatitis B cirrhosis with decompensation and massive ascites,and can significantly reduce ascites.
作者
顾琳娟
Gu Linjuan(Department of Gastroenterology,the First Hospital of Guangshui City in Hubei Province 43270)
出处
《中国社区医师》
2018年第29期32-33,共2页
Chinese Community Doctors
关键词
恩替卡韦
乙肝肝硬化失代偿期
腹水
Entecavir
Decompensation period of hepatitis B liver cirrhosis
Ascites
